RxDoctor Payments Data

Olaoluwa Odofin, MD

Internal Medicine · Huntsville, ALNPI 1134491830

Payments from drug & device makers

$1,344in general payments, 2019–2025

Across 80 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$249
  • Lilly USA, LLC$189
  • Novartis$163
  • IBSA Pharma Inc.$85
  • Astellas Pharma US Inc$76
  • Kowa Pharmaceuticals America, Inc.$61
  • plus $522 from 20 others

What the payments were for

  • Food & beverage$1,344100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,344 in reported general payments places this provider in the 65th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$148,867
Medicare patients
175
Services billed
1,783

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide75$143,893
MounjaroTirzepatide91$132,282
JardianceEmpagliflozin74$67,629
EliquisApixaban65$63,305
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$45,874
Humalog Kwikpen U-200Insulin Lispro14$24,457
XareltoRivaroxaban19$22,616
MyrbetriqMirabegron21$20,452
SynjardyEmpagliflozin/Metformin Hcl14$19,363
Lantus SolostarInsulin Glargine,hum.Rec.Anlog40$11,900
Pitavastatin Calcium22$6,334
Aripiprazole24$4,075
LivaloPitavastatin Calcium13$3,940
Atorvastatin Calcium292$3,671
Levothyroxine Sodium210$2,915

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$249$143,89375 claims
Lilly USA, LLCMounjaro$189$132,28291 claims
Boehringer IngelheimJardiance, Synjardy$16$86,99388 claims
PfizerEliquis$48$63,30565 claims
GSKTrelegy Ellipta$21$45,87428 claims
Astellas Pharma US IncMyrbetriq$76$20,45221 claims
Kowa Pharmaceuticals America, Inc.Livalo$61$3,94013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →